In an interview with the Wall Street Journal, President Trump said he was still considering what to do about subsidy payments to insurers under the Patient Protection and Affordable Care Act (PPAC), which Republicans contend are unconstitutional.

One paradox in an age full of them is the refusal of many people in developed Western countries to take advantage of one of the Western world’s great accomplishments: the drugs that keep so many of us alive and functioning.

People living in areas that restrict trans fats in foods had fewer hospitalizations for heart attack and stroke compared with residents in areas without restrictions, according to a study led by a Yale researcher.

Middle-aged individuals with risk factors for heart attacks and stroke are also more likely to develop changes in the brain that can precede the development of Alzheimer's disease, according to a study led by the Johns Hopkins University School of Medicine.

Historically, the U.S. health care system has not made it easy for people to find out how much their care will cost them out of pocket. Public Agenda, with support from the Robert Wood Johnson Foundation and the New York State Health Foundation, recently conducted a survey to explore how Americans are trying to find and use this information.

The FDA has approved Ingrezza capsules (valbenazine, Neurocrine Biosciences, Inc.) to treat adults with tardive dyskinesia. This is the first and only drug approved by the FDA for this condition. 

The escalating pressure on providers to dramatically change how they organize and deliver care will continue in the years ahead, according to a report from Modern Healthcare. Bottom line-oriented employers, cash-strapped families, and tax-starved governments will insist on it.

Researchers at the University of Nebraska–Lincoln have demonstrated that nesting specialized nanoparticles inside microparticles could protect engineered genes or virus-derived DNA against the rigors of the stomach and ensure safe passage to the intestine.

Kimberly-Clark and its spinoff medical-technology firm Halyard Health have been hit with $454 million in compensatory and punitive damages after a federal jury in Los Angeles found that the companies misled California buyers about the impermeability of their MicroCool surgical gowns, according to an Associated Press report.

Lawmakers from both parties are calling on Congress to establish a dedicated funding source to fight infectious-disease outbreaks, according to an article posted on the Morning Consult website.

The Trump administration says that it is willing to continue paying subsidies to health insurance companies under the Patient Protection and Affordable Care Act (PPACA), according to an article in The New York Times.

Regulators and medical device-makers are bracing for an expected barrage of hacking attacks, according to a report from The Hill. High-profile attacks have hit hospitals and health insurers in recent years, and now attention is turning to a new vulnerability: medical devices, such as pacemakers and insulin pumps.

Talk to your doctor, patients are advised. The U.S. Preventive Services Task Force (USPSTF) has loosened its guidance on whether men should take the prostate-specific antigen (PSA) blood test.

A global phase 3 study has met its primary endpoint, demonstrating that alectinib (Alecensa, Genentech/Roche) as a first-line treatment significantly reduced the risk of disease-worsening or death compared with crizotinib (Zalkori, Pfizer Oncology/EMD Serono) in patients with anaplastic lymphoma kinase (ALK)-positive advanced non–small-cell lung cancer (N

A new study published by JAMA Neurology examines hospitalization rates for acute ischemic stroke in “younger” adults (18 to 64 years of age) by stroke type and patient age, sex, and race/ethnicity, along with associated risk factors.

Pages